Category Health & IP

WHO Bulletin Focusses On BRICS And Global Health

The June edition of the World Health Organization monthly Bulletin is dedicated to public health and the BRICS countries (Brazil, Russia, India, China, and South Africa). That was a key issue of the recent World Health Assembly, as the emerging economies gain strength and coordinate their efforts to improve health access for their citizens, particularly as they graduate from global aid projects.

Get Tested For Hepatitis C! – Interview With Abbott’s Gavin Cloherty

Gavin Cloherty is associate director of scientific affairs at the US molecular diagnosis developer Abbott Molecular. Abbott has a long-standing history of developing tests for detecting and monitoring hepatitis, among other areas. With Intellectual Property Watch, Cloherty discussed the burden of hepatitis C, the process of diagnosis and the importance of diagnosis for curbing and treating the disease.

WHO Makes Headway On New Headquarters Building In Geneva

World Health Organization members last week approved a plan putting the UN health agency on track to renovating its headquarters in Geneva, reducing the number of buildings from 10 to three by eliminating the various longstanding temporary structures (including the restaurant) and constructing a new building adjacent to the existing main building. The main building also would be renovated.

WHO Executive Board Wraps Up Post-WHA Work

At the World Health Organization 135th Executive Board meeting this week, member states discussed improvements to cut down on lengthy World Health Assemblies, and adopted two reports for further discussion on surgical care and anaesthesia, and the health impact of air pollution.

NCDs As Global Policy Concern: WHO Approves Plan To Tackle Scourge

The prevention and control of non-communicable diseases (NCDs) stands high on the agenda of World Health Organization member countries, many of them said last week. Governments called for a multi-stakeholder approach to tackle the problem, governed by firm rules, and some asked for ways to regulate products that increase risk factors.